Is Jazz Pharmaceuticals PLC (JAZZ) overvalued? · P/E 1988, rev $4.07B
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
This page asks whether Jazz Pharmaceuticals PLC (JAZZ) looks expensive on cached numbers — not a short thesis.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next JAZZ 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the JAZZ stock page for the full model, not this heading.
Not investment advice.